ZEVRA THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M |
| Operating income | -$62.9M | -$87.0M | -$49.6M | -$42.6M |
| Cost of revenue | — | — | $2.9M | $222,000 |
| Cash from operations | -$1.6M | -$69.7M | -$33.5M | -$18.7M |
| Capital expenditure | $835,000 | $0 | $296,000 | $93,000 |
| Free cash flow | -$2.4M | -$69.7M | -$33.8M | -$18.8M |
| Share repurchases | — | $0 | $3.4M | $4.7M |
| Impairments | $0 | $0 | $0 | $0 |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M |
| Total liabilities | $130.1M | $138.5M | $110.5M | $40.2M |
| Total debt | $63.6M | $61.6M | — | — |
Shares outstanding 59.1M · Free float 90.9%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.